前言
经济学人浓咖啡马拉松计划doing！第-96天。
喝吧
Profit booster: Pfizer
盆满钵满：辉瑞
Pfizer has had a good year.
今年对辉瑞来说是个井喷年。
The wide adoption of the drugmaker’s covid-19 jab, the first to be rolled out, has given its profits a real shot in the arm.
辉瑞作为第一个推出新冠疫苗的药厂，疫苗的广泛接种让它赚的盆满钵满。
It is on track to produce 3bn doses this year.
今年有望生产出30亿剂疫苗。
America’s drug regulator has just approved its vaccine for children aged 5-11.
美国药监局刚刚批准了辉瑞生产的适用于5至11岁儿童的疫苗。
Next year it expects to almost double covid-vaccine sales.
辉瑞希望明年的新冠疫苗销量达到今年的两倍。
As it reports quarterly results on Tuesday, its upward trajectory shows no signs of slowing.
周二发布的季度报告显示，其销量上升趋势并未见减缓迹象。
Pfizer’s non-covid business is also flourishing, with strong year-on-year growth in the second quarter.
在第二季度报告中显示，辉瑞的非新冠疫苗业务也如火如荼，正以逐年递增的趋势发展。
That trend is likely to continue, as the mRNA technology its covid vaccine employs finds other uses.
因为mRNA技术不仅能用于新冠疫苗的研发，非新冠疫苗的业务趋势可能仍会持续上升。
The recent acquisition of a cancer-drug biotech company for $2.3bn shows Pfizer is looking beyond the pandemic.
最近，辉瑞以23亿美元收购了一家癌症药物生物科技公司（Trillium Therapeutics）。这也说明辉瑞看到了疫情之外的业务机会。
In August the firm raised its 2021 revenue projections.
8月，辉瑞公布了2021年度预期收入。
Thanks to demand for covid-vaccine boosters and the possibility that new variants of the virus will emerge, it may set its sights even higher.
由于新冠疫苗的大量需求，加上新冠病毒新毒株也可能面世，辉瑞的预期收入可能更高。
很多国家推出了疫苗护照，接种了新冠疫苗的旅客才可以入境。
